Life Technologies, CHEO researcher partner to co-develop microbial detection tests

NewsGuard 100/100 Score

Dr. Robert Slinger recognized as expert in field of infectious disease

The Children's Hospital of Eastern Ontario (CHEO) Research Institute is pleased to announce that one of its principal investigators in infectious disease has signed a contract with Life Technologies, an internationally renowned biotech tools company headquartered in Carlsbad, California, to share information that will help to develop tests that uniquely amplify and detect the DNA coding for infectious diseases. Dr. Robert Slinger will focus on bacteria that cause severe infectious diseases.

"I believe Life Technologies to be a leader in its field, so it was an honor to be approached about contributing to this project," said Dr. Slinger, a CHEO Medical Microbiologist and Pediatric Infectious Diseases physician. "Life Technologies is one of the only companies in the world that has the full suite of technology to look at detection of infectious disease agents from extracting DNA and RNA from a sample to amplifying and detecting the results. I think they're ahead of the curve yet again, by bringing microbial testing to their innovation roadmap."

Dr. Slinger and Life Technologies are partnering with the objective to co-develop microbial detection tests. In short, they will identify the unique DNA sequence of targeted infectious disease pathogens which will ultimately be used to create tests that will rapidly and clearly indicate when a targeted infectious agent has been identified in a patient sample. Samples will be tested with "all-inclusive" panels that include tests for large numbers (e.g. 30-50) of infectious agents. This approach will ensure that all possible causes of the patient's infection are looked for at the same time, which Dr. Slinger believes will ultimately lead to better antibiotic treatment for patients.

"Dr. Slinger is well known as one of the first to use molecular panel technology to test for infectious disease in humans," said Astrid Ferlinz, Life Technologies' Global Market Development Manager, Darmstadt, Germany. "We're now embarking on a strategic partnership with Dr. Slinger that will one day alter how we look for infectious disease to help patients; but also to protect the public from contracting serious infections that can't be detected by current lab methods (for instance, consider the E. coli outbreak in Germany this spring)."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rising antibiotic resistance prompts shift to ecological research strategies in infection control